natgillin/translations-raw huggingface dataset:
Coagadex contains the active substance human coagulation factor X.
Coagadex sadrži djelatnu tvar koja se naziva ljudski koagulacijski faktor X.
Coagadex contains traces of human proteins other than factor X. Patients should be informed of the early signs of hypersensitivity reactions including angioedema, infusion site inflammation (e.g. burning, stinging, erythema), chills, cough, dizziness, fever, flushing, generalised urticaria, headache, hives, hypotension, lethargy, musculoskeletal pains, nausea, pruritus, rash, restlessness, tachycardia, tightness of the chest, tingling, vomiting, wheezing.
Coagadex sadrži tragove ljudskih proteina koji nisu faktor X. Bolesnike treba informirati o ranim znakovima reakcija preosjetljivosti uključujući angioedem, upalu na mjestu infuzije (npr. žarenje, peckanje, eritem), zimicu, kašalj, omaglicu, vrućicu, navale crvenila, generaliziranu urtikariju, glavobolju, koprivnjaču, hipotenziju, letargiju, bolove u mišićima i kostima, mučninu, pruritus, osip, nemir, tahikardiju, stezanje u prsištu, trnce, povraćanje, piskanje pri disanju.
Coagadex human coagulation factor X
Coagadex ljudski koagulacijski faktor X
Coagadex is available as a powder and solvent used to make a solution for injection into a vein.
Coagadex je dostupan kao prašak i otapalo od kojih se priprema otopina koja se daje injekcijom u venu.
Coagulase negative
Koagulaza-negativni
Coagulase positive
Koagulaza-pozitivni
Coagulation
Koagulacija
coagulation and bleeding disorders (including activated partial thromboplastin time prolonged), autoantibody test positive (including double stranded DNA antibody), blood lactate dehydrogenase increased
poremećaji koagulacije i krvarenja (uključujući produljenje aktiviranog parcijalnog tromboplastinskog vremena), pozitivan nalaz testa na autoprotutijela (uključujući protutijela na dvolančanu DNK), povišena laktat dehidrogenaza u krvi
coagulation disorders including symptomatic thrombosis related to the use of central venous catheters, hyperglycaemic conditions.
poremećaji koagulacije uključujući simptomatsku trombozu povezanu s upotrebom centralnih venskih katetera hiperglikemijska stanja.
coagulation disorders, aplastic anaemia, haemolytic
poremećaji zgrušavanja, aplastična anemija, hemolitička
coagulation disorders, aplastic anaemia, haemolytic anaemia, lymphadenopa thy
poremećaji zgrušavanja, aplastična anemija, hemolitička
coagulation disorders, aplastic anaemia, haemolytic anaemia, lymphadenopa thy
poremećaji zgrušavanja, aplastična anemija, hemolitička anemija, limfadentopatija
Coagulation factor concentrates (activated or non-activiated) or recombinant Factor VIIa may be taken into account.
U obzir se mogu uzeti koncentrati koagulacijskih faktora (aktivirani ili neaktivirani) ili rekombinantni faktor VIIa.
Coagulation factor V, clotting factor VIII, 2-macroglobulin, and C1-esterase inhibitor are only slightly reduced and normalise within 1 to 2 days.
Vrijednosti koagulacijskog faktora V, faktora VIII, 2-makroglobulina i inhibitora C1-esteraze samo se blago smanjuju, a normaliziraju se tijekom 1 do 2 dana.
Coagulation factor VIII level decreasedb
snižena razina koagulacijskog faktora VIIIb
Coagulation parameters should be monitored at baseline and periodically during and after treatment; particularly when other medicinal products with coagulation-inhibiting effects such as acetylsalicylic acid and nonsteroidal anti-inflammatory medicinal products are used simultaneously (see section 4.5).
Parametre koagulacije treba nadzirati na početku liječenja te periodično tijekom i nakon liječenja, naročito kada se istodobno primjenjuju ostali lijekovi s antikoagulacijskim učinkom, primjerice, acetilsalicilatna kiselina i nesteroidni protuupalni lijekovi (vidjeti dio 4.5).
Coagulation parameters should be monitored in patients treated with concomitant oral anticoagulants (see section 4.5 and 4.8).
U bolesnika istodobno liječenih antikoagulansima treba pratiti parametre koagulacije (vidjeti dio 4.5 i 4.8).
Coagulation parameters, specifically international normalised ratio (INR), should be monitored in the days immediately following the initiation of Pixuvri concurrent therapy.
Potrebno je pratiti koagulacijske parametre, posebice INR (international normalised ratio), već prvih dana nakon započetog liječenja s Pixuvriom.
Coagulation tests affected by telavancin
Pretrage koagulacije na koje je telavancin utjecao
Coagulation tests may become unreliable following adminstration of suggested coagulation factor concentrates.
Testovi koagulacije mogu biti nepouzdani nakon primjene predloženih koncentrata koagulacijskih faktora.
Coagulation tests such as INR, prothrombin time (PT), or activated partial thromboplastin time (aPTT) are not a useful measure of the effect of Lixiana.
Testovi koagulacije kao što su INR, protrombinsko vrijeme (PV) ili aktivirano parcijalno tromboplastinsko vrijeme (aPTV) nisu korisne mjere učinka Lixiane.
Coagulation tests unaffected by telavancin
Pretrage koagulacije na koje telavancin nije utjecao
Coagulation time abnormal, Prothrombin time prolonged
abnormalno vrijeme koagulacije, produženo protrombinsko vrijeme
coagulo- pathies, pancytopenia, neutropenia, coagulation and bleeding analyses, abnormal
koagulopatije, pancitopenija, neutropenija, poremećaj testova koagulacije i krvarenja
coagulopathies, pancytopenia, neutropenia, coagulation and bleeding analyses abnormal
koagulopatije, pancitopenija, neutropenija, poremećeni nalazi koagulacije i krvarenja
coagulopathy (disturbance of blood clotting)
koagulopatija (poremećaj zgrušavanja krvi)
coagulopathy, leukopaenia, eosinophil count increased, platelet count decreased, platelet count increased, lymphocyte count decreased, white blood cell count increased, neutrophil count decreased
anemija, trombocitopenija, koagulopatija, leukopenija, povećani broj eozinofila, smanjeni broj trombocita, povećani broj trombocita, smanjeni broj limfocita, povećani broj leukocita, smanjeni broj neutrofila
Coagulopathy, Red blood cell agglutination, Abnormal clotting factor, Anaemia, Lymphopenia
koagulopatija, aglutinacija crvenih krvnih stanica, poremećaji čimbenika zgrušavanja, anemija, limfopenija
CoAprovel 150 mg/12.5 mg film-coated tablets are peach, biconvex, oval-shaped, with a heart debossed on one side and the number 2875 engraved on the other side.
CoAprovel 150 mg/12,5 mg filmom obložene tablete su bikonveksne, ovalne tablete boje breskve s utisnutom oznakom srca na jednoj i brojem 2875 na drugoj strani.
CoAprovel 150 mg/12.5 mg film-coated tablets.
CoAprovel 150 mg/12,5 mg filmom obložene tablete
CoAprovel 150 mg/12.5 mg may be administered in patients whose blood pressure is not adequately controlled with hydrochlorothiazide or irbesartan 150 mg alone;
CoAprovel 150 mg/12,5 mg može se propisati bolesnicima čiji se krvni tlak ne može na odgovarajući način kontrolirati samo hidroklorotiazidom ili irbesartanom u dozi od 150 mg;
CoAprovel 150 mg/12.5 mg tablets are peach, biconvex, oval-shaped, with a heart debossed on one side and the number 2775 engraved on the other side.
CoAprovel 150 mg/12,5 mg tablete su bikonveksne, ovalne tablete boje breskve s utisnutom oznakom srca na jednoj i brojem 2775 na drugoj strani.
CoAprovel 150 mg/12.5 mg tablets.
CoAprovel 150 mg/12,5 mg tablete
CoAprovel 300 mg/12.5 mg film-coated tablets are peach, biconvex, oval-shaped, with a heart debossed on one side and the number 2876 engraved on the other side.
CoAprovel 300 mg/12,5 mg filmom obložene tablete su bikonveksne, ovalne tablete boje breskve s utisnutom oznakom srca na jednoj i brojem 2876 na drugoj strani.
CoAprovel 300 mg/12.5 mg film-coated tablets.
CoAprovel 300 mg/12,5 mg filmom obložene tablete
CoAprovel 300 mg/12.5 mg may be administered in patients insufficiently controlled by irbesartan 300 mg or by CoAprovel 150 mg/12.5 mg.
CoAprovel 300 mg/12,5 mg može se propisati bolesnicima čiji se krvni tlak ne može na odgovarajući način kontrolirati irbesartanom u dozi od 300 mg ili lijekom CoAprovel 150 mg/12,5 mg.
CoAprovel 300 mg/12.5 mg tablets are peach, biconvex, oval-shaped, with a heart debossed on one side and the number 2776 engraved on the other side.
CoAprovel 300 mg/12,5 mg tablete su bikonveksne, ovalne tablete boje breskve s utisnutom oznakom srca na jednoj i brojem 2776 na drugoj strani.
CoAprovel 300 mg/12.5 mg tablets irbesartan/hydrochlorothiazide
CoAprovel 300 mg/12,5 mg tablete irbesartan/hidroklorotiazid
CoAprovel 300 mg/12.5 mg tablets.
CoAprovel 300 mg/12,5 mg tablete
CoAprovel 300 mg/25 mg film-coated tablets are pink, biconvex, oval-shaped, with a heart debossed on one side and the number 2788 engraved on the other side.
CoAprovel 300 mg/25 mg filmom obložene tablete su bikonveksne, ovalne tablete boje breskve s utisnutom oznakom srca na jednoj i brojem 2788 na drugoj strani.
CoAprovel 300 mg/25 mg film-coated tablets.
CoAprovel 300 mg/25 mg filmom obložene tablete
CoAprovel 300 mg/25 mg tablets irbesartan/hydrochlorothiazide
CoAprovel 300 mg/25 mg tablete irbesartan/hidroklorotiazid
CoAprovel can be taken with or without food.
CoAprovel se može uzeti s hranom ili bez nje.
CoAprovel is a combination of an angiotensin-II receptor antagonist, irbesartan, and a thiazide diuretic, hydrochlorothiazide.
CoAprovel je kombinacija irbesartana, antagonista receptora angiotenzina II i hidroklorotiazida, tiazidskog diuretika.
CoAprovel is not recommended in early pregnancy, and must not be taken if you are more than 3 months pregnant, as it may cause serious harm to your baby if used at that stage (see pregnancy section).
CoAprovel se ne preporučuje uzimati u ranoj trudnoći, a ne smije se uzimati nakon trećeg mjeseca trudnoće jer može ozbiljno naškoditi Vašem djetetu primjenjujete li ga u tom razdoblju (vidjeti dio o trudnoći).
CoAprovel should not be given to children and adolescents (under 18 years).
CoAprovel se ne smije davati djeci i adolescentima (mlađima od 18 godina).
CoAprovel with food and drink
CoAprovel s hranom i pićem
Coarse spray administration and in drinking water use
Primjena raspršivanjem ili putem vode za piće
Coarse spray, oculonasal or in drinking water use.
Raspršivanjem, okulonazalno ili putem vode za piće.
Coated tablet
Obložena tableta.
Coated Tablet
potahované tablety
Coated Tablets
Obložene tablete
Coating
Ovojnica
Coating Hypromellose Macrogol Titanium dioxide
Ovojnica hipromeloza makrogol titanijev dioksid
Coating Macrogol 3350
Ovojnica makrogol 3350
coating of the tongue, difficulty swallowing, abnormal taste after medicine intake
obložen jezik, otežano gutanje, neprirodan okus nakon uzimanja lijeka
Coating: hypromellose, Macrogol 4000, titanium dioxide (E171), and iron oxide yellow (E172).
Ovojnica: hipromeloza, makrogol 4000, titanijev dioksid (E171), željezov oksid žuti (E172).
Coating: hypromellose, povidone, titanium dioxide (E171), yellow iron oxide (E172), propylene glycol, methacrylic acid-ethyl acrylate copolymer, sodium lauril sulfate, polysorbate 80, triethyl citrate.
Ovojnica: hipromeloza, povidon, titanijev dioksid (E171), žuti željezov oksid (E172), propilenglikol, metakrilatna kiselina/etilakrilat kopolimer 1:1, natrijev laurilsulfat, polisorbat 80, trietilcitrat.
Coating: polyvinyl alcohol, titanium dioxide (E171), talc, polyethylene glycol and lecithin (soy)
Ovojnica: poli(vinilni alkohol), titanijev dioksid (E171), talk, polietilenglikol i lecitin (soja)
cobicistat
kobicistato
Cobicistat (150 mg once daily)
Elvitegravir (150 mg jedanput na
Cobicistat acts as a ‘booster’ to enhance the effects of darunavir, by prolonging the time in which it acts in the body.
Kobicistat djeluje kao „booster“ kako bi pojačao djelovanje darunavira, produljujući vrijeme djelovanja u tijelu.
Cobicistat and cobicistat- containing products
Kobicistat i lijekovi koji sadrže kobicistat
Cobicistat as a pharmacokinetic enhancer of darunavir should, therefore, not be initiated in patients with creatine clearance less than 70 ml/min if any co-administered agent requires dose adjustment based on creatinine clearance: e.g. emtricitabine, lamivudine, tenofovir disoproxil fumarate or adefovir dipovoxil.
Prema tome, kobicistat koji se koristi kao farmakokinetički pojačivač darunavira se ne smije se početi davati bolesnicima s klirensom kreatinina manjim od 70 ml/min, ako bilo koji od istodobno primijenjenih lijekova zahtijeva prilagodbu doze temeljenu na klirensu kreatinina: npr. emtricitabin, lamivudin, tenofovir dizoproksilfumarat ili adefovir dipovoksil.
Cobicistat as a pharmacokinetic enhancer of darunavir should, therefore, not be initiated in patients with creatine clearance less than 70 ml/min if any co-administered agent requires dose adjustment based on creatinine clearance: e.g. emtricitabine, lamivudine, tenofovir disoproxil fumarate or adefovir dipovoxil.
Prema tome, kobicistat koji se koristi kao farmakokinetički pojačivač darunavira se ne smije se početi davati bolesnicima s klirensom kreatinina manjim od 70 ml/min, ako bilo koji od istodobno primijenjenih lijekova zahtjeva prilagodbu doze temeljenu na klirensu kreatinina: npr. emtricitabin, lamivudin, tenofovir dizoproksilfumarat ili adefovir dipovoksil.
Cobicistat AUC ↔
Kobicistat AUC ↔
Cobicistat Cmax ↔
Kobicistat Cmax ↔
Cobicistat Cmin ↑232%
Kobicistat Cmin ↑232
Cobicistat exposures are non-linear and greater than dose-proportional over the range of 50 mg to 400 mg, consistent with a mechanism-based CYP3A inhibitor.
Izloženosti kobicistatu bile su nelinearne i veće nego proporcionalno dozi u rasponu od 50 mg do 400 mg te dosljedne s inhibitorom temeljenim na mehanizmu CYP3A.
Cobicistat exposures were unaffected by a light meal and although there was a modest decrease of 24% and 18% in Cmax and AUC respectively with a high-fat meal, no difference was observed in its pharmacoenhancing effect on elvitegravir.
Lagani obrok nije utjecao na izloženost kobicistatu, iako je došlo do umjerenog pada vrijednosti Cmax i AUC od 24%, odnosno 18% s visokomasnim obrokom, nikakva razlika nije zapažena u njegovom pojačavajućem farmakološkom učinku na elvitegravir.
Cobicistat has not been studied in patients over the age of 65.
Kobicistat nije ispitivan u pacijenata starijih od 65 godina.
Cobicistat has not been studied in patients receiving dialysis, and, therefore, no recommendation can be made for the use of darunavir/cobicistat in these patients.
Kobicistat nije ispitan u bolesnika na dijalizi, stoga se, preporuke za primjenu darunavira/kobicistata u ovih bolesnika, ne mogu dati.
Cobicistat has not been studied in patients receiving dialysis, and, therefore, no recommendation can be made for these patients.
Kobicistat nije proučavan u pacijenata koji su na dijalizi i stoga se ne mogu dati preporuke za te pacijente.
Cobicistat has not been studied in patients with severe hepatic impairment (Child-Pugh Class C).
Kobicistat nije ispitivan u bolesnika s teškim oštećenjem jetrene funkcije (Child-Pugh stadij C).
Cobicistat has not been studied in patients with severe hepatic impairment (Child-Pugh Class C).
Kobicistat nije ispitivan u pacijenata s teškim oštećenjem jetre (Child-Pugh stadij C).
Cobicistat inhibits the transporters p-glycoprotein (P-gp), BCRP, MATE1, OATP1B1 and OATP1B3.
Kobicistat inhibira p-glikoprotein (P-gp) transportere, BCRP, MATE1, OATP1B1 i OATP1B3.
Cobicistat inhibits the transporters p-glycoprotein (P-gp), BCRP, MATE1, OATP1B1 and OATP1B3.
Kobicistat inhibira p-glikoprotein transportere (P-gp), BCRP, MATE1, OATP1B1 i OATP1B3.
Cobicistat is a potent CYP3A inhibitor.
Kobicistat je snažan inhibitor CYP3A4.
Cobicistat is a strong mechanism-based CYP3A inhibitor and a CYP3A substrate.
Kobicistat je jak mehanički inhibitor CYP3A i supstrat CYP3A.
Cobicistat is a strong mechanism-based CYP3A inhibitor and is a CYP3A substrate.
Kobicistat je jaki CYP3A inhibitor temeljen na mehanizmu i supstrat je CYP3A.
Cobicistat is an inhibitor of the following transporters: P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), organic anion transporting polypeptide (OATP) 1B1 and OATP1B3.
Kobicistat je inhibitor sljedećih transportera: P-glikoproteina (P-gp), proteina rezistencije raka dojke na lijekove (BCRP), transportnog polipeptida za organske anione (OATP) 1B1 i OATP1B3.
cobicistat is expected to increase
kobicistata povisiti plazmatske
Cobicistat is not indicated for use in twice daily regimens or for use in the pediatric population.
Kobicistat nije indiciran za primjenu u režimu doziranja dva puta na dan ili za primjenu u pedijatrijskoj populaciji.
cobicistat lowers the creatinine
kobicistatom snižava klirens kreatinina.
Cobicistat reversibly inhibits MATE1, and concentrations of metformin may be increased when co-administered with cobicistat.
Kobicistat reverzibilno inhibira MATE1, stoga se koncentracije metformina mogu povećati s istovremenom primjenom kobicistata.
Cobicistat reversibly inhibits MATE1, and concentrations of metformin may be increased when co-administered with Stribild.
Kobicistat reverzibilno inhibira MATE1, stoga se koncentracije metformina mogu povećati s istovremenom primjenom Stribilda.
cobicistat should not be used in
kobicistatom se ne smije uzimati u
cobicistat should not be used in combination with another
PREZISTA istodobno primijenjena s kobicistatom se ne smije uzimati u
cobicistat, a booster (pharmacokinetic enhancer) of the effects of elvitegravir
kobicistat, pojačivač (farmakokinetički pojačivač) učinaka elvitegravira
cobicistat, a booster (pharmacokinetic enhancer) to help improve the effects of atazanavir.
kobicistat, pojačivač (farmakokinetički pojačivač) koji poboljšava učinke atazanavira.
Cobicistat-
Liječenje
Cobicistat-containing medicinal products
Lijekovi koji sadrže kobicistat
cobicistat.
kobicistat.
cobicistat.
kobicistata.
cobicistat.
koju uzrokuje kobicistat.
Cobicistat: AUC: ↑ 53%
Kobicistat: AUC: ↑ 53
Cobicistat: AUC: ↑ 59%
Kobicistat: AUC: ↑ 59
Cobicistat: AUC: ↓ 84%
Kobicistat: AUC: ↓ 84
Cobicistat: AUC: ↔
Kobicistat: AUC: ↔
Cobimetinib and its metabolites were characterised in a mass balance study in healthy subjects.
Kobimetinib i njegovi metaboliti okarakterizirani su u ispitivanju masene bilance u zdravih ispitanika.
Cobimetinib is a reversible, selective, allosteric, oral inhibitor that blocks the mitogen-activated protein kinase (MAPK) pathway by targeting the mitogen-activated extracellular signal-regulated kinase (MEK) 1 and MEK 2 which results in inhibition of phosphorylation of the extracellular signal- regulated kinase (ERK) 1 and ERK 2.
Kobimetinib je reverzibilan, selektivan, alosterički inhibitor za peroralnu primjenu koji blokira signalni put proteinskih kinaza aktiviranih mitogenom (engl. mitogen-activated protein kinase, MAPK) tako što ciljano djeluje na mitogenom aktivirane kinaze (engl. mitogen-activated kinase) MEK 1 i MEK 2 regulirane izvanstaničnim signalom, što dovodi do inhibicije fosforilacije kinaza reguliranih izvanstaničnim signalom (engl. extracellular signal-regulated kinase) ERK 1 i ERK 2.
Cobimetinib plus Vemurafenib (n = 247) (%)
Kobimetinib plus vemurafenib (n = 247) (%)
Coccidia:
Kokcidije:
Coccidioidomycosis
Kokcidioidomikoza
Coefficient of variation (%)
Koeficijent varijacije (%)
Coexisting conditions
Popratne bolesti
Coexisting inflammatory/autoimmune disorders
Istovremeni upalni/autoimuni poremećaji
Cognitive disorder Motor dysfunction
kognitivni poremećaj, motorička disfunkcija
Cognitive disorder Somnolence Tremor Nystagmus Hypoesthesia Dysarthria Disturbance in attention Paraesthesia
Nistagmus Hipoestezija Dizartrija Poremećaj pažnje Parestezija
cognitive disorder, lethargy, dysgeusia
kognitivni poremećaj, letargija, disgeuzija
Cognitive impairment, confusional state, hallucination, depression (see section 4.5), anxiety, abnormal dreams, insomnia
oštećenje kognitivne funkcije, stanje konfuzije, halucinacije, depresija (vidjeti dio 4.5), anksioznost, abnormalni snovi, nesanica
Cogwheel rigidity
Rigiditet s fenomenom zupčanika
Cohort 1 with previously untreated patients (N = 90): Patients who had not received previous treatment for brain metastases; prior systemic therapy for metastatic melanoma was allowed, excluding BRAF inhibitors and MEK inhibitors.
Prvu kohortu činili su prethodno neliječeni bolesnici (N = 90): bolesnici koji prethodno nisu primili liječenje za moždane metastaze; bila je dopuštena prethodna sistemska terapija za metastatski melanom uz izuzetak BRAF inhibitora i MEK inhibitora.
Cohort 2 with previously treated patients (N = 56): Patients who had been previously treated for their brain metastases and had progressed following this treatment.
Drugu kohortu činili su prethodno liječeni bolesnici (N = 56): bolesnici koji su prethodno primili liječenje za moždane metastaze i kojima je bolest uznapredovala nakon tog liječenja.
COIN: This was an open-label, 3-arm, randomised study in 2445 patients with inoperable metastatic or locoregional colorectal cancer who had not received prior treatment for metastatic disease and compared oxaliplatin plus fluoropyrimidines (infusional 5-fluorouracil/folinic acid [OxMdG] or capecitabine [XELOX]) in combination with cetuximab to the same chemotherapy regimen alone.
COIN: To je bilo otvoreno, randomizirano ispitivanje u tri- skupine na 2445 bolesnika s neoperabilnim metastatskim ili lokoregionalnim kolorektalnim karcinomom koji nisu primali prethodno liječenje za metastatsku bolest a usporedilo je oksaliplatin i fluoropirimidine (infuzijski 5-fluorouracil/folna kiselina [OxMdG] ili kapecitabin [XELOX] u kombinaciji s cetuksimabom s istim režimom kemoterapije kao samostalnim lijekom.
colchicine (anti-gout medicine) – patients with renal or hepatic impairment;
kolhicin (lijek za liječenje gihta) – bolesnici s oštećenjem funkcije bubrega ili jetre;
Colchicine (for gout) as Norvir may raise the blood levels of this medicine.
Kolhicin (za liječenje gihta) jer Norvir može povisiti razine ovog lijeka u krvi.
colchicine (for gout) some calcium channel blockers (e.g. verapamil, nifedipine, felodipine) (for heart disorders).
kolhicin (za liječenje gihta) neke blokatore kalcijevih kanala (npr. verapamil, nifedipin, felodipin) (za liječenje srčanih poremećaja).
Colchicine (if you have kidney and/or liver problems)
kolhicin (ako imate tegobe s bubregom i/ili jetrom)
Colchicine (P-gp substrate)
Kolhicin (Supstrat za P-gp)
Colchicine (to treat gout)
kolhicin (za liječenje gihta)
colchicine (used to treat gout), if you have kidney and/or liver problems ticagrelor (used to reduce the blood clots)
kolhicin (primjenjuje se za liječenje gihta), ako imate bubrežne i/ili jetrene tegobe tikagrelor (primjenjuje se za smanjenje zgrušavanja krvi)
Colchicine Concentrations of colchicine are expected to increase when coadministered with ritonavir.
Kolhicin Očekuju se povećane koncentracije kolhicina pri istodobnoj primjeni s ritonavirom.
colchicine for patients whose kidney and liver function test are normal
kolhicin za bolesnike kod kojih su testovi pokazali normalnu funkciju bubrega i jetre
colchicine in patients who have severe problems with their liver or kidneys
kolhicin u bolesnika koji imaju teške tegobe s jetrom ili bubrezima
colchicine in patients with renal impairment due to an increased risk of severe adverse reactions
kolhicin u bolesnika s oštećenjem bubrega zbog povećanog rizika od teških nuspojava
colchicine in patients with renal or hepatic impairment
kolhicin u bolesnika s oštećenom funkcijom bubrega ili jetre
Colchicine plasma concentrations may be increased when co- administered with EVOTAZ.
Koncentracije kolhicina u plazmi mogu porasti kod istodobne primjene s lijekom EVOTAZ.
Colchicine plasma concentrations may be increased when co-administered with cobicistat.
Istovremena primjena neuroleptika s kobicistatom može za posljedicu imati povećane koncentracije neuroleptika u plazmi.
Colchicine plasma concentrations may be increased when co-administered with cobicistat.
Koncentracije kolhicina u plazmi mogu se povećati kod istovremene primjene s kobicistatom.
colchicine prescribing
lopinavirom/ritonavirom mora
colchicine prescribing
svojstava lijeka za kolhicin.
Colchicine single dose
Kolhicin u jednokratnoj
Colchicine single dose
normalnom funkcijom bubrega ili